Chaos Reigns in Congo as Trump Aid Blow, War Stretch Healthcare
About 5,500 injured in Goma, with dozen more arriving daily
Central African country faces multiple outbreaks of disease
By
Save
Health services are at breaking point in rebel-controlled eastern Democratic Republic of Congo as fighting continues and the situation is exacerbated by the US government's decision to cut funding.
Care givers are struggling to treat thousands of war-wounded and to stay on top of several deadly diseases amid intimidation, looting and dwindling supplies, Health Minister Roger Kamba said by phone Thursday. Congo's health system that's largely supported by external aid is in 'true chaos,' he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
2 days ago
- Entrepreneur
Jashvik Capital Commits Over INR 400 Cr to Marg ERP for Digital Push in Pharma and Healthcare
The funding aims to accelerate product innovation, enhance customer focus, and drive expansion across both domestic and international markets. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Jashvik Capital, a mid‑market private equity firm, has announced an investment exceeding INR 400 crore in Marg ERP, a leading Indian provider of ERP and inventory management software for small and medium enterprises. The funding aims to accelerate product innovation, enhance customer focus, and drive expansion across both domestic and international markets. Founded in 2000 by Anup Singh Thakur, Sudhir Singh Thakur and Mahendar Singh, Marg ERP has developed significant expertise in the pharmaceutical value chain. The company claims to serve more than 500,000 subscribers across healthcare, FMCG and retail sectors in India and 32 other countries. In India, almost half of the pharmaceutical distribution and retail businesses use Marg's software solutions. Its growth rate of over 25 percent annually has been largely driven by word‑of‑mouth referrals and supported by more than 850 channel partners across over 650 cities. The investment from Jashvik Capital is expected to help Marg ERP pursue both organic and inorganic growth strategies. Anup Singh Thakur, Chairman and Managing Director of Marg ERP, said, "We look forward to leveraging Jashvik Capital's deep expertise in healthcare, pharma and health tech to take Marg to its next orbit and build a global healthcare SaaS leader out of India. By empowering industry participants like retailers, distributors, manufacturers, hospitals and physicians, we aim to enhance patient access to affordable healthcare and help improve patient outcomes. Together, we plan to build a truly world‑class healthcare technology infrastructure company. We also plan to deepen our footprint in international markets through our recently launched cloud‑based accounting and ERP product, Marg Book." Naresh Patwari, Founder and Managing Partner at Jashvik Capital, said, "Having known the founders of Marg ERP for the past seven to eight years, we have consistently been impressed by their strategic foresight and passion for using technology to empower entrepreneurs and businesses in the healthcare sector. The founders, their talented employees and their committed channel partners have built a strong, resilient business that is well‑positioned to grow as Indian healthcare shifts toward a value and outcomes‑based model. We are particularly impressed with how Marg is enabling pharmaceutical companies through its ECOD platform and its AI‑enabled ordering and payment solutions." This marks the fourth investment from Jashvik Capital Fund I and aligns with the firm's strategy of supporting founder‑led businesses that address large‑scale real‑world challenges. The financial details of the transaction remain undisclosed. Earlier this year, Marg ERP's founders repurchased a 49 percent stake previously held by API Holdings, parent company of PharmEasy and Thyrocare.
Yahoo
7 days ago
- Yahoo
3 Asian Penny Stocks With Market Caps Below US$10B
Amid a backdrop of favorable trade deals and positive market sentiment, Asian markets have been buoyed by renewed optimism. This environment provides a fertile ground for penny stocks, which, despite the outdated terminology, continue to offer intriguing opportunities for investors. These stocks typically represent smaller or newer companies that can combine affordability with growth potential when supported by strong financials and fundamentals. Top 10 Penny Stocks In Asia Name Share Price Market Cap Financial Health Rating Food Moments (SET:FM) THB4.02 THB3.97B ★★★★★☆ Lever Style (SEHK:1346) HK$1.46 HK$921.19M ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$2.51 HK$2.09B ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.485 SGD196.57M ★★★★★☆ Goodbaby International Holdings (SEHK:1086) HK$1.20 HK$2B ★★★★★★ T.A.C. Consumer (SET:TACC) THB4.60 THB2.76B ★★★★★★ China Sunsine Chemical Holdings (SGX:QES) SGD0.70 SGD667.37M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.54 SGD10B ★★★★★☆ Ekarat Engineering (SET:AKR) THB0.95 THB1.4B ★★★★★★ Livestock Improvement (NZSE:LIC) NZ$0.95 NZ$135.23M ★★★★★★ Click here to see the full list of 970 stocks from our Asian Penny Stocks screener. Let's take a closer look at a couple of our picks from the screened companies. Alibaba Health Information Technology Simply Wall St Financial Health Rating: ★★★★★★ Overview: Alibaba Health Information Technology Limited is an investment holding company that operates in pharmaceutical direct sales, pharmaceutical e-commerce platforms, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of approximately HK$77.99 billion. Operations: The company's revenue from the distribution and development of pharmaceutical and healthcare products is CN¥30.60 billion. Market Cap: HK$77.99B Alibaba Health Information Technology has demonstrated significant earnings growth, with a notable increase of 62.1% over the past year, surpassing its five-year average of 52.2%. The company reported revenues of CN¥30.60 billion for the fiscal year ending March 31, 2025, and improved net profit margins to 4.7%. Despite a one-off loss impacting recent results, Alibaba Health remains debt-free and trades below its estimated fair value by approximately 12.6%. Its short-term assets comfortably cover both short- and long-term liabilities, although the board's average tenure is relatively inexperienced at three years. Click here and access our complete financial health analysis report to understand the dynamics of Alibaba Health Information Technology. Gain insights into Alibaba Health Information Technology's future direction by reviewing our growth report. Shanghai Trendzone Holdings GroupLtd Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.74 billion, offers integrated solutions in design, construction, production, and services both in China and internationally. Operations: No specific revenue segments have been reported for Shanghai Trendzone Holdings Group Co., Ltd. Market Cap: CN¥3.74B Shanghai Trendzone Holdings Group Co., Ltd, with a market cap of CN¥3.74 billion, has shown some financial resilience despite being unprofitable. Its short-term assets of CN¥1.3 billion comfortably cover both short- and long-term liabilities, indicating solid liquidity management. The company's debt to equity ratio has improved over five years to 42.5%, suggesting prudent debt management, while its net debt to equity ratio is satisfactory at 35.3%. However, the firm remains unprofitable with a negative return on equity of -9.78% and faces high share price volatility alongside less than one year of cash runway based on current free cash flow trends. Dive into the specifics of Shanghai Trendzone Holdings GroupLtd here with our thorough balance sheet health report. Assess Shanghai Trendzone Holdings GroupLtd's previous results with our detailed historical performance reports. Leo Group Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Leo Group Co., Ltd. operates in China through its subsidiaries, focusing on the research, development, manufacture, and sale of pumps and garden machinery products with a market cap of CN¥24.94 billion. Operations: No specific revenue segments are reported for Leo Group Co., Ltd. Market Cap: CN¥24.94B Leo Group Co., Ltd. has a market cap of CN¥24.94 billion and operates in China, focusing on pumps and garden machinery products. Despite having more cash than total debt, its operating cash flow covers only 12.3% of the debt, indicating potential liquidity concerns. The company's net profit margin decreased to 0.4% from 5.6% last year, with earnings declining by 33.2% annually over five years due to a significant one-off loss of CN¥388.7M affecting recent results as of March 2025. While short-term assets exceed liabilities significantly, the dividend yield remains poorly covered by earnings or free cash flows. Unlock comprehensive insights into our analysis of Leo Group stock in this financial health report. Evaluate Leo Group's historical performance by accessing our past performance report. Key Takeaways Embark on your investment journey to our 970 Asian Penny Stocks selection here. Looking For Alternative Opportunities? The latest GPUs need a type of rare earth metal called Neodymium and there are only 25 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:241 SHSE:603030 and SZSE:002131. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data
Fast Company
24-07-2025
- Fast Company
UnitedHealth Group confirms DOJ investigation over Medicare billing
BY UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading Medicare business. The health care giant said Thursday that it had contacted the Department of Justice after reviewing media reports about investigations into certain elements of its business. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper has since said that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth said in the filing Thursday that it 'has full confidence in its practices and is committed to working cooperatively with the Department throughout this process.' UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than $400 billion in revenue last year as the third-largest company in the Fortune 500. Its share price topped $630 last fall to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A suspect, Luigi Mangione, has been charged in connection with the shooting. In April, shares plunged some more after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned, and the company withdrew its forecast entirely, saying that medical costs from new Medicare Advantage members were higher than expected. The stock price slipped another 3%, or $10.35, to $282.16 in midday trading Thursday. That represents a 55% drop from its all-time high. The Dow Jones Industrial Average, of which UnitedHealth is a component, also fell slightly. Meanwhile, the broader S&P 500 rose. UnitedHealth will report its second-quarter results next Tuesday. —Tom Murphy, AP health writer
